KINDRED BIOSCIENCES, INC. (NASDAQ:KIN) Files An 8-K Regulation FD Disclosure


KINDRED BIOSCIENCES, INC. (NASDAQ:KIN) Files An 8-K Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.

Kindred Biosciences, Inc. (the Company) intends to make
presentations, which will include a business update to investors.
A copy of the Companys presentation is furnished as Exhibit 99.1
to this current report on Form 8-K and incorporated under this
Item 7.01 by reference.
The information contained in this Item 7.01, including Exhibit
99.1, shall not be deemed filed for any purpose, and shall not be
deemed incorporated by reference to any filing under the
Securities Act of 1933, as amended, or the Securities Exchange
Act of 1934, as amended, regardless of any general incorporation
language in any such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Kindred Biosciences, Inc. Investor Presentation


Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company’s other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.


KINDRED BIOSCIENCES, INC. (NASDAQ:KIN) closed its last trading session up +0.03 at 4.22 with 20,039 shares trading hands.